Literature DB >> 15166955

Inflammatory mechanisms contributing to pancreatic cancer development.

Buckminster Farrow1, Yuko Sugiyama, Andy Chen, Ekong Uffort, William Nealon, B Mark Evers.   

Abstract

OBJECTIVE: Pancreatic cancer is the most deadly of all gastrointestinal (GI) malignancies, yet relatively little is known regarding mechanisms of tumor development including the role of inflammation. SUMMARY BACKGROUND DATA: Chronic pancreatitis (CP) increases the risk of developing cancer by 10- to 20-fold; mediators of the chronic inflammatory process and the surrounding fibrotic stroma likely support a transformation to malignancy, yet the exact mechanisms remain undefined. The purpose of our present study was to determine potential inflammatory components in epithelial and stromal cells that may contribute to both CP and pancreatic cancers.
METHODS: Specimens of normal pancreas, CP, and pancreatic cancer were examined using laser-capture microdissection (LCM), gene array, and immunohistochemistry.
RESULTS: Gene array analysis from LCM-dissected tissues demonstrated: (i) increased expression of interleukin-8 (IL-8), an activator of the inflammatory factor nuclear factor-kappaB (NF-kappaB), and (ii) decreased expression of IkappaB (an inhibitor of NF-kappaB) in CP ductal cells compared with normal ducts. Compared with CP, cancers demonstrated: (i) increased expression of tumor related genes including S100A4, cyclin E1, and epidermal growth factor (EGF) receptor, and (ii) expression of matrix metalloproteinase 2, a pro-invasive factor for tumor cells, which was not present in the CP stroma. Increased staining of both the p50 NF-kappaB subunit and IKKalpha kinase (a protein that allows activation of NF-kappaB) was noted in CP and cancers.
CONCLUSIONS: Our results demonstrate that similar inflammatory components and downstream effectors are present in CP and pancreatic cancers. Importantly, these findings suggest that a common pathway for pancreatic cancer development may be through a chronic inflammatory process including stroma formation. These findings may lead to novel strategies for pancreatic cancer prophylaxis based on inhibition of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166955      PMCID: PMC1360122          DOI: 10.1097/01.sla.0000128681.76786.07

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  46 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis.

Authors:  N Howes; J P Neoptolemos
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 3.  Chemokines: new, key players in the pathobiology of pancreatic cancer.

Authors:  Karen E Hedin
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation.

Authors:  Christophe Rosty; Takashi Ueki; Pedram Argani; Marnix Jansen; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

6.  Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells.

Authors:  S Philip; A Bulbule; G C Kundu
Journal:  J Biol Chem       Date:  2001-09-19       Impact factor: 5.157

7.  Selective inhibition of NF-kappaB attenuates the severity of cerulein-induced acute pancreatitis.

Authors:  Richard T Ethridge; Koji Hashimoto; Dai H Chung; Richard A Ehlers; Srinivasan Rajaraman; B Mark Evers
Journal:  J Am Coll Surg       Date:  2002-10       Impact factor: 6.113

Review 8.  Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems.

Authors:  Makoto Otsuki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

9.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

10.  Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells.

Authors:  Koji Hashimoto; Richard T Ethridge; B Mark Evers
Journal:  Int J Gastrointest Cancer       Date:  2002
View more
  50 in total

Review 1.  Microbial pigments as natural color sources: current trends and future perspectives.

Authors:  Hardeep S Tuli; Prachi Chaudhary; Vikas Beniwal; Anil K Sharma
Journal:  J Food Sci Technol       Date:  2014-10-10       Impact factor: 2.701

Review 2.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

3.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

4.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

5.  Pancreatic cancer in chronic pancreatitis.

Authors:  Puneet Dhar; S Kalghatgi; Vivek Saraf
Journal:  Indian J Surg Oncol       Date:  2015-01-21

6.  Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal:  J Gastrointest Surg       Date:  2013-02-23       Impact factor: 3.452

7.  Risk factors for pancreatic cancer: case-control study.

Authors:  Manal M Hassan; Melissa L Bondy; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Peter W Pisters; Douglas B Evans; Rabia Khan; Ta-Hsu Chou; Renato Lenzi; Li Jiao; Donghui Li
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

Review 8.  Obesity, pancreatitis, and pancreatic cancer.

Authors:  Andrew A Gumbs
Journal:  Obes Surg       Date:  2008-06-19       Impact factor: 4.129

9.  Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

Authors:  Jennifer Kl Colby; Russell D Klein; Mark J McArthur; Claudio J Conti; Kaoru Kiguchi; Toru Kawamoto; Penny K Riggs; Amy I Pavone; Janet Sawicki; Susan M Fischer
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.

Authors:  Annika Lehmann; Carsten Denkert; Jan Budczies; Ann-Christin Buckendahl; Silvia Darb-Esfahani; Aurelia Noske; Berit Maria Müller; Marcus Bahra; Peter Neuhaus; Manfred Dietel; Glen Kristiansen; Wilko Weichert
Journal:  BMC Cancer       Date:  2009-11-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.